Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib

Oncology (Switzerland)

Volumn 89, Issue 2, 2015, Pages 88-94

  Ganten, Maria Katharina ^a,b   Schuessler, Max ^a   Bruckner, Thomas ^a   Ganten, Tom M ^a   Koschny, Ronald ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Department of Diagnostic and Interventional Radiology and Nuclear Medicine ^*  (Germany)

Author keywords

Hepatocellular carcinoma; Pancreatic atrophy; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

ADULT; AGED; ARTICLE; ATROPHY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; MALE; ORGAN SIZE; OVERALL SURVIVAL; PANCREATIC ATROPHY; PANCREATIC VOLUME; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; LIVER NEOPLASMS; MIDDLE AGED; PANCREAS; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ATROPHY; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PANCREAS; PHENYLUREA COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937525675     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000377681     Document Type: Article

References (17)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
3. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al: Early skin toxicity as a predictive factor for tumor control in hepa-tocellular carcinoma patients treated with sorafenib. Oncologist 2010; 15:85-92.
4. Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM: Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology 2013; 84:6-13.
5. Bettinger D, Schultheiss M, Knuppel E, Thimme R, Blum HE, Spangenberg HC: Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology 2012; 56:789-790.
6. Hescot S, Vignaux O, Goldwasser F: Pancreatic atrophy-a new late toxic effect of sorafenib. N Engl J Med 2013; 369:1475-1476.
7. Bruix J, Sherman M: Management of hepato-cellular carcinoma. Hepatology 2005; 42: 1208-1236.
8. Maleike D, Nolden M, Meinzer HP, Wolf I: Interactive segmentation framework of the Medical Imaging Interaction Toolkit. Comput Methods Programs Biomed 2009; 96:72-83.
9. Wolf I, Vetter M, Wegner I, Bottger T, Nolden M, Schobinger M, et al: The medical imaging interaction toolkit. Med Image Anal 2005; 9: 594-604.
10. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-943.
11. Mir O, Coriat R, Boudou-Rouquette P, Du-rand JP, Goldwasser F: Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2012; 23:280-281.
12. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 2010; 28:1054-1060.
13. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP: Sorafenib induced thyroiditis in two patients with hepa-tocellular carcinoma. Thyroid 2011; 21:197-202.
14. Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, et al: Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroen-terol 2014; 20:12581-12587.
15. Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, et al: Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int 2013; 33:950-957.
16. Poprach A, Pavlik T, Melichar B, Puzanov I, Dusek L, Bortlicek Z, et al: Skin toxicity and efficacy of sunitinib and sorafenib in meta-static renal cell carcinoma: a national registry-based study. Ann Oncol 2012; 23:3137-3143.
17. Song T, Zhang W, Wu Q, Kong D, Ma W: A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors. Eur J Gastro-enterol Hepatol 2011; 23:1233-1238.